Research
Researchers identify DNA marker that could predict treatment response in myelodysplastic syndromes
The Brief
- A multicenter study reports that DNA methylation patterns present at diagnosis may help predict which myelodysplastic syndrome (MDS) patients will respond to azacitidine.
- The finding comes from a new study involving researchers at Sylvester Comprehensive Cancer Center, according to a Medical Xpress report dated 2026-11-10.
Why it matters
If validated, a diagnostic methylation marker could help clinicians decide earlier which MDS patients are likely to benefit from azacitidine, a standard hypomethylating therapy.
Who’s affected
- clinicians and patients with myelodysplastic syndromes
- cancer researchers working on epigenetic biomarkers
- #myelodysplastic syndromes
- #azacitidine
- #dna methylation
- #biomarkers
- #cancer treatment
DNA methylation patterns present at diagnosis could help predict which patients with myelodysplastic syndromes (MDS) will respond to azacitidine. That's the key finding of a new multicenter study involving researchers at Sylvester Comprehensive Cancer Center, part of the…
Timeline
Medical Xpress reports the multicenter study findings on DNA methylation as a predictor of azacitidine response in MDS
Medical Xpress - latest medical and health news stories
Researchers identify DNA marker that could predict treatment response in myelodysplastic syndromes